5 results match your criteria: "Denver (M.R.N.); and Baptist Cardiac and Vascular Institute[Affiliation]"
Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD.
Circulation
May 2024
Colorado Prevention Center Clinical Research, Aurora, CO (J.T.M., M.E.C., M.R.N., C.N.H., J.H., W.H.C., S.D.B., M.P.B.).
Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PAD.
Circulation
February 2024
Department of Medicine, University of Colorado, Aurora (S.E.H., S.D.B., M.P.B.).
Contemporary management of traumatic cervical and thoracic esophageal perforation: The results of an Eastern Association for the Surgery of Trauma multi-institutional study.
J Trauma Acute Care Surg
October 2020
From the Division of Acute Care Surgery, Department of Surgery (L.A.R.), University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Ascension St. John Medical Center Trauma Services (E.A.S.), Tulsa, Oklahoma; Department of Surgery (R.G.M., B.R.H.R.), Harborview Medical Center, University of Washington School of Medicine, Seattle, Washington; Division of Acute Care Surgery, Department of Surgery (J.J.), University of Alabama at Birmingham, Birmingham, Alabama; Department of Surgery (M.R.N., Z.S.), Allegheny General Hospital, Pittsburgh, Pennsylvania; Department of General Surgery (E.C., J.C.), Denver Health Medical Center, Denver, Colorado; University of Nevada at Las Vegas School of Medicine (S.S., J.T.C.), Las Vegas, Nevada; Department of Trauma (L.E.J., J.W.), St. Vincent Indianapolis Hospital, Indianapolis, Indiana; Department of Surgery (A.J.Y., J.P.), University of Pennsylvania, Philadelphia, Pennsylvania; Department of Surgery (S.B., D.G.), Loma Linda Medical Center, Loma Linda, California; Division of Trauma, Burns, and Surgical Critical Care, Department of Surgery (J.N.), University of California at Irvine, Orange, California; Department of Surgery (M.E.K.), University of Mississippi Medical Center, Jackson, Mississippi; Division of Trauma and Acute Care Surgery, Department of Surgery (N.B., K.J.), Tufts Medical Center, Boston, Massachusetts; and Division of Acute Care Surgery, Department of Surgery (P.B.), Banner University Medical Center, University of Arizona College of Medicine, Phoenix, Arizona.
Background: Traumatic esophageal perforation is rare and associated with significant morbidity and mortality. There is substantial variability in diagnosis and treatment. Esophageal stents have been increasingly used for nontraumatic perforation; however, stenting for traumatic perforation is not yet standard of care.
View Article and Find Full Text PDFDominant Role for Regulatory T Cells in Protecting Females Against Pulmonary Hypertension.
Circ Res
June 2018
From the Stanford University School of Medicine, Department of Medicine, CA (R.T., P.M., T.S., J.Q., M.S., L.P.N., A.L., M.R., A.H., L.A., M.R.N.)
Rationale: Pulmonary arterial hypertension (PH) is a life-threatening condition associated with immune dysregulation and abnormal regulatory T cell (Treg) activity, but it is currently unknown whether and how abnormal Treg function differentially affects males and females.
Objective: To evaluate whether and how Treg deficiency differentially affects male and female rats in experimental PH.
Methods And Results: Male and female athymic rats, lacking Tregs, were treated with the VEGFR2 (vascular endothelial growth factor receptor 2) inhibitor SU5416 or chronic hypoxia and evaluated for PH; some animals underwent Treg immune reconstitution before SU5416 administration.
Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease.
N Engl J Med
July 2015
From Massachusetts General Hospital, Boston (K.R., M.R.J.); Ochsner Medical Center, New Orleans (C.J.W.); Prairie Heart Institute at St. John's Hospital, Springfield, IL (K.R.-S.); Yale School of Medicine, New Haven, CT (C.M.-H.); Wellmont Cardiovascular Associates Heart Institute, Kingsport, TN (D.C.M.); Medical University of Graz, Graz, Austria (M.B., E.P.); University Heart Center Freiburg-Bad Krozingen, Bad Krozingen (T.Z.), Diakonissenanstalt zu Flensburg, Flensburg (S.M.-H.), and Park-Krankenhaus Leipzig and Universitätsklinikum Leipzig, Leipzig (D.S.) - all in Germany; Mount Sinai Medical Center, New York (P.K.); Austin Heart, Austin, TX (R.G.); University of Colorado Medical Center, Denver (M.R.N.); and Baptist Cardiac and Vascular Institute, Miami (J.F.B.).
Background: The treatment of peripheral artery disease with percutaneous transluminal angioplasty is limited by the occurrence of vessel recoil and restenosis. Drug-coated angioplasty balloons deliver antiproliferative agents directly to the artery, potentially improving vessel patency by reducing restenosis.
Methods: In this single-blind, randomized trial conducted at 54 sites, we assigned, in a 2:1 ratio, 476 patients with symptomatic intermittent claudication or ischemic pain while at rest and angiographically significant atherosclerotic lesions to angioplasty with a paclitaxel-coated balloon or to standard angioplasty.